Cover Page - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 04, 2026 |
Jun. 30, 2025 |
|
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Registrant Name | Dianthus Therapeutics, Inc. | ||
| Trading Symbol | DNTH | ||
| Entity Central Index Key | 0001690585 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Emerging Growth Company | false | ||
| Entity Small Business | true | ||
| Entity Shell Company | false | ||
| Entity Tax Identification Number | 81-0724163 | ||
| Entity Public Float | $ 599.4 | ||
| Title of 12(b) Security | Common Stock | ||
| Entity Interactive Data Current | Yes | ||
| Security Exchange Name | NASDAQ | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Address, Address Line One | 7 Times Square, 43rd Floor | ||
| Entity Address, City or Town | New York | ||
| Entity Address, Postal Zip Code | 10036 | ||
| Entity Address, State or Province | NY | ||
| Securities Act File Number | 001-38541 | ||
| City Area Code | 929 | ||
| Local Phone Number | 999-4055 | ||
| Entity Common Stock, Shares Outstanding | 44,471,094 | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Documents Incorporated By Reference | DOCUMENTS INCORPORATED BY REFERENCE Certain information required to be included in Part III of this Annual Report on Form 10-K is set forth in, and incorporated by reference from, the Registrant’s definitive proxy statement for its 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after December 31, 2025. |
||
| Auditor Firm ID | 34 | ||
| Auditor Name | Deloitte & Touche LLP | ||
| Auditor Location | Morristown, New Jersey | ||
| Auditor Opinion [Text Block] | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Dianthus Therapeutics, Inc. (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity and cash flows, for each of the two years in the period ended December 31, 2025 and 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. |